摘要
B细胞受体(B cell receptor,BCR)信号通路的慢性持续性激活在B细胞血液系统疾病的发生发展中发挥关键作用。布鲁顿酪氨酸激酶(Burton's tyrosine kinase,BTK)是该信号通路中的一个重要激酶。通过靶向BTK而调控BCR信号通路的传导,已成为治疗多种B细胞淋巴瘤的新方向。第一代BTK抑制剂——伊布替尼在治疗B细胞恶性肿瘤中取得了突破性进展,但仍有部分患者出现原发或继发耐药。此外,由于脱靶效应,不良反应也较为明显。因此,近年来新型BTK抑制剂的研发及其与其他药物的联合治疗引起了研究者们的关注。本文就BTK抑制剂在B细胞淋巴瘤治疗中相关的临床研究进展进行综述。
The chronic and sustainable activation of B cell receptor(BCR)signaling pathway plays a key role in the development of B-cell malignancies.Burton's tyrosine kinase(BTK)is an important kinase in this signal pathway.To regulate BCR pathway by targeting BTK has become a direction in the treatment of B-cell lymphoma.Ibrutinib,the first generation BTK inhibitor,has achieved a breakthrough effect in the treatment of B-cell lymphoma,but some patients have developed primary or secondary resistance to this agent.In addition,there are side effects due to the off-target effect of ibrutinib.Therefore,in recent years,the development of new BTK inhibitors and the combination therapy of BTK inhibitors with other drugs have attracted the attention of researchers.In this paper,the related clinical research progresses of BTK inhibitors in the treatment of B-cell lymphomas is reviewed.
作者
于慧
邓丽娟
朱军
Yu Hui;Deng Lijuan;Zhu Jun(Department of Lymphoma,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Beijing Cancer Hospital&Institute,Beijing 100142,China)
出处
《肿瘤综合治疗电子杂志》
2020年第2期29-35,共7页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
国家自然科学基金项目(81670187)。
